Thus, PD-L1 may be a potential target in predicting response to chemotherapy in metastatic bladder cancer, being a possible promising strategy for individualized targeted therapy with selection of patients that mostly benefit from chemotherapy or immunotherapy. This evidence concerns the gene CD274 and urinary bladder cancer.